Thank you for your interest in Combining Immunotherapy with Stereotactic Radiotherapy: A Paradigm Shift?
If you missed the live event, we invite you to watch the replay.
Recent advances in combining immunotherapy with stereotactic radiotherapy have opened the door for a paradigm shift in the way metastatic cancers are treated. Significant technological advances permit multiple metastatic tumors to be targeted effectively with radiotherapy. Increasingly, this advanced radiotherapy is being combined with the latest immunotherapy drugs to transform cancer care.
In this webinar, Dr. Andrew Sharabi (radiation oncologist) and Dr. Sandip Patel (medical oncologist) will speak with moderator Dr. Ricky Sharma about the current status of this exciting combination of therapies. They will discuss clinical factors in patient selection, the value of a multi-disciplinary team, and how to deliver the most effective treatment for each patient.
Andrew Sharabi, M.D., PhD
Andrew Sharabi is a physician-scientist and board-certified radiation oncologist at UC San Diego Moores Cancer Center. He is also the Associate Director of Translational Research in the Center for Precision Radiation Medicine (CPRM) and Director of the Moores Cancer Center Radiation Medicine Core Facility. A dedicated Basic and Translational Scientist, his research focus is on understanding the fundamental interactions between radiation and the immune system, and on identifying strategies to combine radiation with immunotherapies. He is the Principal Investigator of an NIH R01 Grant focused on adaptive immune responses in Head/Neck cancer and a Co-Investigator on a prestigious NIH Moonshot U01 Grant evaluating neo-antigen T-cell responses in Head/Neck cancer. He is also the PI of a large investigator-initiated randomized phase II clinical trial combining immunotherapy and SBRT. In addition to being a researcher, Dr. Sharabi is also a clinician and a member of the Head & Neck and GU Cancer Disease Teams. He serves on multiple Department and National Committees including Chair of the Immunotherapy Track for the American Society for Radiation Oncology (ASTRO) Education Committee.
Sandip P. Patel, M.D.
Sandip Patel is an Associate Professor at UCSD and a medical oncologist focused on early development of novel immunotherapy, in particular early phase clinical trials of cancer immunotherapy and thoracic oncology immunotherapy trials. His lab focuses on computational immunopathology to derive spatial immune signatures that can inform novel immune target discovery. Dr. Patel is triple board-certified in internal medicine, medical oncology, and hematology and was named a “Top Doc” in the most recent San Diego Magazine Physicians of Exceptional Excellence survey. He is co-leader for the Experimental Therapeutics (Phase 1) Program and Deputy Director for the Center for Precision Immunotherapy at UCSD. He is Director of the Clinical Trials Office at UCSD Moores Cancer Center and a member of the Cancer Immunotherapy, Experimental Therapeutics (Phase 1), and Thoracic Oncology Programs. Dr. Patel is the co-leader of the NRG Developmental Therapeutics Committee.
Ricky Sharma, M.D., PhD
Ricky Sharma is Vice President of Clinical Affairs at Varian, where he leads medical research, translational science, and clinical trials for Varian's growing oncology business. Dr. Sharma is an international authority on the translation of radiobiology from the laboratory to the clinic, on the multi-modality treatment of cancer with precision radiotherapy, and on internal radiotherapy and chemotherapy treatments for patients with liver metastases. Dr. Sharma has served as the global chief investigator in 15 Phase I, II, or III clinical trials in the fields of radiation, medical, and interventional oncology, including pivotal multi-center, randomized controlled trials testing new drug-radiotherapy combinations which have enrolled over 2,000 cancer patients. He is a Fellow of the Royal College of Physicians and the Royal College of Radiologists and he has published over 200 articles in scientific journals. Prior to joining Varian, Dr. Sharma was the Chair of Radiation Oncology at University College, London, UK, where he continues as an honorary clinical professor.
Programs for sharing emerging ideas among thought leaders from across the globe, designed to spark inspiration, accelerate innovation, and advance patient care.